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HypertriglyceridemiaSea-blue histiocytosis is a rare condition that can be often identiﬁed in bonemarrow, spleen, liver aswell as other
organs. It can be frequently detected in bone marrow of patients with myeloproliferative neoplasms as well as
non-neoplastic conditions such as idiopathic thrombocytopenic purpura. In this study,we report pathologicﬁnd-
ings in a case of sea-blue histiocytosis of spleen in a patientwho presentedwith abdominal pain and elevated tri-
glycerides. The sea-blue histiocytosis was identiﬁed as an unexpected ﬁnding in this previously healthy
individual. This case illustrates the necessity of good communication between clinicians and pathologists for
the identiﬁcation and treatment of the underlying lipid disorders. The prior cases of sea-blue histiocytosis report-
ed in English literature are reviewed and the differential diagnoses are discussed.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Sea-blue histiocytosis (SBH) is a rare condition that was originally
described by Moeschlin and Silverstein in 1947 and 1970 respectively
[1–3]. Since its original description, multiple different biochemical etiolo-
gies for this condition have been proposed, [4,5] indicating that the
presence of sea-blue histiocytes does not signify a distinct entity. While
sea blue histiocytes are most commonly concentrated in the spleen,
bone marrow, and liver, [1–11] they have also been described in many
other locations, including the lungs [12] and skin [13]. They are frequently
observed in the bonemarrowof patientswith a variety of both neoplastic
and non-neoplastic conditions including myelodysplastic and myelopro-
liferative neoplasms [8], idiopathic thrombocytopenic purpura [7], auto-
immune neutropenia [10], thalassemia and increased intramedullary
cell destruction. In addition, there are isolated case reports of sea-blue
histiocytes in the marrow of patients receiving total parenteral nutrition
[14,15]. The presence of sea-blue histiocytes within the spleen may be
indicative of one of the following disorders of lipid metabolism:
Niemann-Pick disease, Gaucher disease, cholesterol ester storage disease,
severe hypertriglyceridemia, Tangier disease, and lecithin-cholesterol
acyltransferase deﬁciency [4]. Splenic SBHmay also be seen in other con-
ditions including in association with light chain deposition disease. [16].
Since “sea-blue histiocytosis” is a non-speciﬁc descriptive term, it is
essential for the pathologist who examines and reviews a surgical speci-
men with sea-blue histiocytosis to list the differential diagnoses and. This is an open access article under
, Splenic sea-blue (ceroid) his
http://dx.doi.org/10.1016/j.esuggest the appropriate laboratory work-up needed to further character-
ize a potential underlying lipid disorder or other conditions as presented
in this paper. This is particularly relevant in our case, when sea-blue
histiocytosis was identiﬁed in a splenectomy specimen as an incidental
and unexpected ﬁnding in a previously healthy individual. We report
a case of incidental splenic sea-blue histiocytosis in a 32-year-old,
previously healthy femalewho presentedwith splenomegaly and clinical
suspicion of splenic rupture and was subsequently found to have severe
hypertriglyceridemia.
1.1. Case report
A 32-year-old Hispanic female with no signiﬁcant past medical
history presented with new onset, severe (9/10), left-sided abdominal
pain that radiated to her back. On admission, the pain had been present
for two days and was progressively increasing in severity. The patient
denied experiencing similar pain in the past. She denied fevers, chills,
night sweats, weight loss, or recent viral illness. She had cesarean
sections for all three of her children. In the Emergency Department, an
abdominal computed tomography (CT) scan revealed splenomegaly
(spleen 18.8 cm) with possible small splenic rupture, as well as marked
hepatic steatosis. She was admitted and had an extensive diagnostic
work-up. Laboratory investigations revealed a total cholesterol of
218 mg/dL, triglycerides level of 1790 mg/dL, and HDL level of 10 mg/dL.
LDL was not calculated. She had a normal CBC, peripheral blood
smear, electrolytes, coagulation panel, and liver function tests. Lipase
and amylase levels were not tested on admission. Of note, she did
have mild hyperglycemia during her hospital stay, but her hemoglobinthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
tiocytosis due to hypertriglyceridemia: Report of a case and review of
hpc.2016.03.007
A. Low power view of H&E-stained histologic   
B. PAS-stained histologic section of spleen treated  
2 K.A. Krehbiel et al. / Human Pathology: Case Reports xxx (2016) xxx–xxxA1C was normal at 5.2%. Her hepatitis panel, HIV, Epstein-Barr virus IgM
and cytomegalovirus IgMwere negative. She had a negative rheumato-
logic workup.
During her hospitalization, the patient remained in severe pain that
could not be controlled despite aggressive titration with narcotic
analgesics. The etiology of the splenic enlargement remained unclear.
The patient was referred to the surgical service for splenectomy,
which was performed on hospital Day 5.
2. Materials & methods
2.1. Splenectomy specimen
The spleen was received fresh in the surgical pathology laboratory,
weighed 421 g, and measured 19.1 × 11.5 × 6.0 cm. Gross examination
revealed a smooth and intact gray capsule without grossly identiﬁable
tear or rupture. The cut surface was pale pink and ﬂuctuant without
discrete nodules or lesions (Fig. 1). Representative sections were
submitted for histologic evaluation.
2.2. Immunohistochemistry and histochemical stains
Parafﬁn immunohistochemical stains were performed using CD3
(Ventana, predilute), CD8 (Ventana, predilute), CD20 (Dako, 1:800 dilu-
tion), CD68 (Dako, 1:50 dilution), and S-100 (Biocare, 1:400 dilution).
Brieﬂy, 4-μm in thickness recuts of parafﬁn-embedded splenic tissue
were baked for 30min in an oven at 60 °C. Deparafﬁnization, antigen re-
trieval, blockage of endogenous peroxidase activity, antibody dispense
and incubation steps were all performed using an automated Ventana
Benchmark Ultra instrument. After completion of run, the slides were
removed from the Ventana instrument, dipped 10–15 times in dilute
Dawn detergent in water to remove the oil, rinsed in tap water,
dehydrated using graded alcohols, dipped in xylene and coverslipped
for microscopic examination.
Hematoxylin and eosin stains and special stains, including periodic
acid-Schiff (PAS) with and without diastase and Giemsa stains were
performed using the manufacturer protocols.
3. Results
3.1. Histomorphologic ﬁndings
Review of the hematoxylin and eosin stain of the splenic sections
revealed abundant foamy histiocytes within the splenic cords of the
red pulp and intact white pulp (Fig. 2A). The histiocytes containedFig. 1. Gross image of cut surface of spleen showing a pale-pink, ‘greasy’ appearance.
C. Giemsa-stained section of spleen highlight several  
Fig. 2. (A) Low-power view of H&E-stained histologic section of spleen demonstrates
expansion of red pulp by numerous histiocytes. (B) PAS-stained histologic section of
spleen treated with diastase shows numerous PAS-positive diastase-resistant granules
in sea-blue histiocytosis. (C) Giemsa-stained section of spleen highlights several ceroid
(sea-blue) histiocytes with abundant intracytoplamic blue granules.
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Total cholesterol 218 mg/dL 224 mg/dL b200 mg/dL
Triglycerides 1790 mg/dL 449 mg/dL b150 mg/dL
HDL cholesterol 10 mg/dL 36 mg/dL N40 mg/dL
LDL particle number 2430 nmol/L b1000 nmol/L
Small LDL particle number 1754 nmol/L ≤527 nmol/L
LDL particle size 19.5 nm N20.5 nm
Large HDL particle number 2.4 μmol/L ≥4.8 μmol/L
Large VLDL particle number 29.5 nmol/L ≤2.7 μmol/L
HDL size 9.0 nm ≥9.2 nm
VLDL size 59.3 nm ≥46.6 nm
HDL particle number 36.5 μmol/L ≥30.5 μmol/L
LP insulin resistance score 76 ≤45
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dant foamy intracellular material within the histiocytes had a ﬁne
homogenous appearance and lacked the characteristic “tissue paper”
appearance classically described in Niemann-Pick and Gaucher disease.
No signiﬁcant extramedullary hematopoiesis or other morphologic
abnormalities were appreciated.
3.2. Immunohistochemical and histochemical ﬁndings
The foamy histiocytes expressed CD68 and lacked S-100 protein.
Stains for CD20 and CD3 revealed a normal distribution of splenic B-
and T-cells with no increase in CD20-positive B-cells. CD8 outlined the
splenic sinuseswhich did not contain foamy histiocytes. In situ hybridiza-
tion for EBV (EBER) showed no EBV-infected cells. Approximately 15% of
the histiocytes demonstrated stainingwith PASwith andwithout diastase
(Fig. 2B) and exhibited brilliant azure staining by Giemsa (Fig. 2C),
conﬁrming that the histiocytes were in fact sea blue histiocytes.
4. Discussion
Since the original description of so-called sea-blue histiocytosis
(SBH), several biochemical etiologies have been proposed for this entity
[4,5]. The diverse etiologic entities indicate that SBH is not a distinct
entity. Therefore, it is essential for pathologists who examine and
review a surgical specimen with SBH to list the differential diagnoses
and suggest the appropriate laboratory work-up to further characterize
a potential underlying lipid disorder and other causes of SBH.
SBH in the spleen is a phenomenonmost commonly associated with
one of the following genetically based dyslipidemias: Niemann-Pick
type C disease and lipoprotein lipase (LpL) deﬁciency due to either a
primary defect in the enzyme itself or a mutation in apolipoprotein
C-II (apoC-II) [17–19], the obligatory activator of LpL. Circulating lipo-
protein lipase is the main enzyme responsible for the catabolism of
plasma triglycerides which occur in plasma mainly as a component
of VLDL and chylomicrons. The hallmark of insufﬁcient LpL activity
is hypertriglyceridemia. Although an elevated plasma triglyceride
concentration is found in patients with any of the aforementioned
dyslipidemias, a level exceeding 1000 mg/dL is rare and usually the
result of LpL deﬁciency. Furthermore, the incidence of familial LpL deﬁ-
ciency is extremely low (approximately 1/106) and much less common
than that of apoC-II deﬁciency. HDL plays an important role in the hy-
drolysis of the triglyceride component of VLDL and chylomicrons be-
cause HDL functions as a circulating reservoir of apoC-II and apo-E3,
which activate LpL. The apoC-II from HDL interacts with LpL enzyme
that is bound to VLDL and hydrolysis of triglyceride ensues. While apo-
lipoprotein E3 (ApoE3) also stimulates triglyceride hydrolysis by LpL, it
is physiologically less signiﬁcant in this regard than apoC-II.
Given the histologicﬁndings, a broaddifferential diagnosiswas raised
as possible underlying etiologies for the splenic SBH in the case reported
here with markedly elevated triglyceride levels. The pathologic ﬁndings
and differential diagnosis were presented at an interdisciplinary
conference, with a brief discussion of the need to further evaluate this
patient for an underlying lipid disorder.
The main differential diagnoses of SBH in patients with hyper-
lipidemia include Tangier disease [20] versus chylomicronemia [21].
Patients with Tangier disease typically present with markedly enlarged
orange or yellow tonsils, splenomegaly, hepatomegaly, neuropathy,
cloudy cornea and early atherosclerosis. The lipid proﬁle includes
severe reduction of HDL and mildly elevated triglyceride with accu-
mulation of cholesterol in many body tissues including the spleen.
Individuals with chylomicronemia typically present with markedly
elevated triglycerides (typically N1000 mg/dL) that may accompany by
eruptive xanthoma, lipemia retinalis and recurrent acute pancreatitis.
The features suggestive of Tangier disease were not evident in the case
reported here.Please cite this article as: K.A. Krehbiel, et al., Splenic sea-blue (ceroid) his
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family and internal medicine. She had not been started on any medica-
tions. Molecular genetic testing was not performed. However, a nuclear
magnetic resonance (NMR) lipid panel performed 10 weeks after sple-
nectomy revealed numerous abnormalities as listed in Table 1.
The clinical presentation (severe abdominal pain, splenomegaly,
hepatosteatosis) and laboratory ﬁndings (markedly elevated total
plasma triglycerides, elevated VLDL, low HDL, slightly elevated total
cholesterol, elevated amylase) in the present case conformmost closely
to a deﬁciency of LpL activity resulting from a compound mutation in
apoC-II, the primary cofactor for circulating LpL and surface constituent
of VLDL and chylomicrons. Many different mutations affecting the LpL-
activating function of apoC-II have been identiﬁed. The absence of
palmar xanthomas in our patient does not preclude the diagnosis of
apo-C-II deﬁciency since xanthomas are less common in apoC-II deﬁ-
ciency than LpL deﬁciency [22], and are evident in only about half of
the cases of LpL deﬁciency. Our patient's clinical and laboratory ﬁndings
are not consistent with Niemann-Pick disease, which usually manifests
before adulthood and presents with a normal or near-normal total
cholesterol and plasma triglycerides that are not elevated N2.5-fold.
The reason why the concentration of HDL is reduced in individuals
with primary LpL deﬁciency or mutations in apoC-II is uncertain.
Perhaps the presence of a mutant form of apoC-II on the surface of
HDL particles predisposes them to uptake and catabolism in the liver.
Regardless of the cause of the hypertriglyceridemia, the increased
risk of additional triglyceride injury to the pancreas and liver is a
compelling reason to initiate therapy aimed at promptly lowering the
plasma triglyceride level. This treatment can be accomplished with
triglyceride-lowering drugs such as ﬁbrates, niacin, marine ﬁsh oil,
and statins. Invariably, a low-fat diet is also recommended for patients
with hypertriglyceridemia. LpL deﬁciency has been successfully treated
by replacement of dietary fat comprised of long-chain fatty acids with
those containing medium-chain fatty acids.
5. Conclusion
This case highlights the importance of recognizing the broad dif-
ferential diagnosis for sea-blue histiocytosis as well as the importance
of good communication between the surgical team, pathologist, and
clinicians to ensure that patients receive adequate work-up and treat-
ment. Because the underlying etiologies of sea-blue histiocytosis in
a subset of cases are genetic in nature, referral for genetic counseling
is essential to identify other family members at risk. Conversely, it is
critical to rule out non-genetic acquired sources of hyperlipidemia,
including medications, prior to initiating a genetic work-up.
An additional consideration in patients with lipoprotein lipase deﬁ-
ciency or similar lipid disorders is the importance of starting medical
therapy early to avoid surgical complications. Since the patient presented
here had imagingﬁndings concerning splenic rupture aswell as intracta-
ble abdominal pain, splenectomy was indicated in this case. However,tiocytosis due to hypertriglyceridemia: Report of a case and review of
hpc.2016.03.007
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lipids are preferentially deposited and not the primary source of disease.
Early recognition of lipid abnormalities (particularly very high levels of
triglycerides) with initiation of appropriate lipid-lowering medications
may obviate the need for splenectomy. Following hospitalization, the
patient was advised to maintain a low-fat diet and was started on
ﬁsh oil supplements. In the following months her triglyceride levels
declined signiﬁcantly and her HDL increased. Unfortunately, additional
genetic and/or enzymatic testing was not performed due to difﬁculties
in follow-up.
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